Macitentan | B1856

Macitentan is an orally active endothelin receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH).

Macitentan is an orally active endothelin receptor antagonist (ERA) approved for the treatment of pulmonary arterial hypertension (PAH).

B1856 | Macitentan DataSheet

Alternate Name/Synonyms: N-[5-(4-bromophenyl)-6-{2-[(5-bromopyrimidin-2-yl)oxy]ethoxy}pyrimidin-4-yl]-N'- propylsulfamide; ACT-064992

Appearance: Crystalline solid

Formulation: N/A

CAS Number: 441798-33-0

Structure Available?: Yes

Peptide sequence: N/A

Salt Form: N/A

Molecular Formula: C₁₉H₂₀Br₂N₆O₄S

Molecular Weight: 588.27

Cell-Permeable?: Yes

Purity: ≥98% by HPLC

Solubilities: DMSO

Handling: Protect from air and light

Country of Origin: USA

Tag Line: An orally active endothelin receptor antagonist (ERA)

MDL Number: N/A

PubChem CID: 16004692

SMILES: CCCNS(=O)(=O)NC1=C(C(=NC=N1)OCCOC2=NC=C(C=N2)Br)C3=CC=C(C=C3)Br

InChi: InChI=1S/C19H20Br2N6O4S/c1-2-7-26-32(28,29)27-17-16(13-3-5-14(20)6-4-13)18(25-12-24-17)30-8-9-31-19-22-10-15(21)11-23-19/h3-6,10-12,26H,2,7-9H2,1H3,(H,24,25,27)

InChi Key: JGCMEBMXRHSZKX-UHFFFAOYSA-N